24.63
-0.50 (-1.99%)
| Penutupan Terdahulu | 25.13 |
| Buka | 25.58 |
| Jumlah Dagangan | 3,331,925 |
| Purata Dagangan (3B) | 1,511,315 |
| Modal Pasaran | 2,171,343,360 |
| Harga / Buku (P/B) | 3.26 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.75 |
| Nisbah Semasa (MRQ) | 26.48 |
| Aliran Tunai Operasi (OCF TTM) | -192.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -122.17 M |
| Pulangan Atas Aset (ROA TTM) | -35.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Mineralys Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.63 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.40% |
| % Dimiliki oleh Institusi | 103.83% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Catalys Pacific, Llc | 31 Mar 2026 | 7,903,838 |
| Andera Partners | 31 Mar 2026 | 1,591,917 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |